(3S,4R)-3-[(R)-1-(t-butyldimethylsilyloxy)ethyl]-4-[(R)-2-imidazol-1-yl-1-methyl-2-oxoethyl]azetidin-2-one | 124667-64-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: (3S,4R)-3-[(R)-1-(t-butyldimethylsilyloxy)ethyl]-4-[(R)-2-imidazol-1-yl-1-methyl-2-oxoethyl]azetidin-2-one
• 英文别名: (3S,4R)-3-[(1R)-1-[tert-butyl(dimethyl)silyl]oxyethyl]-4-[(2R)-1-imidazol-1-yl-1-oxopropan-2-yl]azetidin-2-one
• CAS: 124667-64-7
• 化学式: C₁₇H₂₉N₃O₃Si
• 分子量: 351.521
• InChiKey: PVRZROQJCDGVMZ-AAVRWANBSA-N

物化性质

• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.68
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  73.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (3S,4R)-3-[(R)-1-(t-butyldimethylsilyloxy)ethyl]-4-[(R)-2-imidazol-1-yl-1-methyl-2-oxoethyl]azetidin-2-one 在 rhodium (II) acetate dimer dihydrate 、 4-dodecylbenzenesulfonyl azide 、 triethylamine tris(hydrogen fluoride) 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 29.5h， 生成 pivaloyloxymethyl (1R,5S,6S)-2-[(3S,5S)-5-(N,N-dimethylcarbamoyl)-1-(isobutyryloxymethyloxycarbonyl)pyrrolidin-3-ylthio]-6-[(1R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylate
  参考文献：
  名称：

  Novel prodrugs of meropenem with two lipophilic promoieties: synthesis and pharmacokinetics

  摘要：

  为了改善美罗培南（MEPM）的口服吸收，我们合成并评估了一系列双促渗前药，在这些前药中，疏水性促渗基团被引入到羧基和吡咯烷基团中。在这些前药中，匹伐酸氧甲基（1R，5S，6S）-2-[(3S，5S)-5-(N，N-二甲基氨基甲酰基)-1-(异丁酰氧甲基氧羰基)吡咯烷-3-基硫]-6-[(1R)-1-羟基乙基]-1-甲基碳青霉烯-2-烯-3-羧酸酯（4）和1-乙基丙氧基羰氧甲基（1R，5S，6S）-2-[(3S，5S)-5-(N，N-二甲基氨基甲酰基)-1-(异丁酰氧甲基氧羰基)吡咯烷-3-基硫]-6-[(1R)-1-羟基乙基]-1-甲基碳青霉烯-2-烯-3-羧酸酯（8）被选为进一步评估的对象。化合物4和8在大鼠和比格犬中口服后被良好吸收（生物利用度为18.2-38.4%），并预期在感染各种病原体的患者中显示出强大的疗效，例如耐青霉素的肺炎链球菌和耐β内酰胺酶阴性的氨苄西林流感嗜血杆菌。

  DOI：

  10.1038/ja.2010.164
• 作为产物：
  描述：

  4-乙酰氧基氮杂环丁酮 在 N-乙基哌啶 、 tin(II) trifluoromethanesulfonate 作用下， 以 乙腈 为溶剂， 反应 6.5h， 生成 (3S,4R)-3-[(R)-1-(t-butyldimethylsilyloxy)ethyl]-4-[(R)-2-imidazol-1-yl-1-methyl-2-oxoethyl]azetidin-2-one
  参考文献：
  名称：

  .beta.-Lactams. 3. Asymmetric total synthesis of new non-natural 1.beta.-methylcarbapenems exhibiting strong antimicrobial activities and stability against human renal dehydropeptidase-I

  摘要：

  Asymmetric synthesis of 11, the precursor to chiral (3R,4R)-3-[(1R)-1-[(tert-butyldimethylsilyl)oxy]ethyl]-4-acetoxyazetidin-2-one (3) was achieved by utilizing a highly diastereoselective aldol-type reaction of acetaldehyde and the chiral tin(II) enolate of 5. Similar diastereoselective alkylations of chiral and achiral tin(II) enolates 13a-d with chiral 3 were also performed to obtain the desired alkylated azetidin-2-ones (17a-d). Compounds 17a,b were successfully converted to new, non-natural 1-beta-methylcarbapenems 1a and 1b, which exhibited strong and wide-ranging antimicrobial activities and excellent stability against human renal dehydropeptidase-I.

  DOI：

  10.1021/jo00041a033

文献信息

• 美罗培南中间体MAP的制备方法
  申请人：山东金城医药化工有限公司

  公开号：CN115521338A

  公开（公告）日：2022-12-27

  本发明属于医药技术领域，具体涉及一种美罗培南中间体MAP的制备方法。4BMA酰化，镁盐合成，镁盐和4BMA酰化物的反应，重氮化，脱保护基，环合，缩合，得到美罗培南中间体MAP。本发明从控制体系水分、提高绿色溶剂使用量、优化生产工序三个方面来提高收率、降低成本、减少三废产生，工艺高效、利润高，适合大规模工业化生产。
• EP1561748
  申请人：——

  公开号：——

  公开（公告）日：——
• .beta.-Lactams. 3. Asymmetric total synthesis of new non-natural 1.beta.-methylcarbapenems exhibiting strong antimicrobial activities and stability against human renal dehydropeptidase-I
  作者：Yoshimitsu Nagao、Yunosuke Nagase、Toshio Kumagai、Hiroshi Matsunaga、Takao Abe、Osamu Shimada、Takaaki Hayashi、Yoshinori Inoue

  DOI：10.1021/jo00041a033

  日期：1992.7

  Asymmetric synthesis of 11, the precursor to chiral (3R,4R)-3-[(1R)-1-[(tert-butyldimethylsilyl)oxy]ethyl]-4-acetoxyazetidin-2-one (3) was achieved by utilizing a highly diastereoselective aldol-type reaction of acetaldehyde and the chiral tin(II) enolate of 5. Similar diastereoselective alkylations of chiral and achiral tin(II) enolates 13a-d with chiral 3 were also performed to obtain the desired alkylated azetidin-2-ones (17a-d). Compounds 17a,b were successfully converted to new, non-natural 1-beta-methylcarbapenems 1a and 1b, which exhibited strong and wide-ranging antimicrobial activities and excellent stability against human renal dehydropeptidase-I.
• Novel prodrugs of meropenem with two lipophilic promoieties: synthesis and pharmacokinetics
  作者：Shunkichi Tanaka、Hiroshi Matsui、Masayasu Kasai、Kazuyoshi Kunishiro、Nobuharu Kakeya、Hiroaki Shirahase

  DOI：10.1038/ja.2010.164

  日期：2011.3

  To improve the oral absorption of meropenem (MEPM), we synthesized and evaluated a series of its double-promoiety prodrugs, in which lipophilic promoieties were introduced into carboxyl and pyrrolidinyl groups. Among these prodrugs, pivaloyloxymethyl (1R,5S,6S)-2-[(3S,5S)-5-(N,N-dimethylcarbamoyl)-1-(isobutyryloxymethyloxycarbonyl)pyrrolidin-3-ylthio]-6-[(1R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylate (4) and 1-ethylpropyloxycarbonyloxymethyl (1R,5S,6S)-2-[(3S,5S)-5-(N,N-dimethylcarbamoyl)-1-(isobutyryloxymethyloxycarbonyl)pyrrolidin-3-ylthio]-6-[(1R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylate (8) were chosen for further evaluation. Compounds 4 and 8 were well absorbed after oral administration to rats and beagles (bioavailability 18.2–38.4%), and expected to show potent therapeutic efficacy in patients infected with various pathogens, such as penicillin-resistant S. pneumoniae and β-lactamase-negative ampicillin-resistant H. influenzae.

  为了改善美罗培南（MEPM）的口服吸收，我们合成并评估了一系列双促渗前药，在这些前药中，疏水性促渗基团被引入到羧基和吡咯烷基团中。在这些前药中，匹伐酸氧甲基（1R，5S，6S）-2-[(3S，5S)-5-(N，N-二甲基氨基甲酰基)-1-(异丁酰氧甲基氧羰基)吡咯烷-3-基硫]-6-[(1R)-1-羟基乙基]-1-甲基碳青霉烯-2-烯-3-羧酸酯（4）和1-乙基丙氧基羰氧甲基（1R，5S，6S）-2-[(3S，5S)-5-(N，N-二甲基氨基甲酰基)-1-(异丁酰氧甲基氧羰基)吡咯烷-3-基硫]-6-[(1R)-1-羟基乙基]-1-甲基碳青霉烯-2-烯-3-羧酸酯（8）被选为进一步评估的对象。化合物4和8在大鼠和比格犬中口服后被良好吸收（生物利用度为18.2-38.4%），并预期在感染各种病原体的患者中显示出强大的疗效，例如耐青霉素的肺炎链球菌和耐β内酰胺酶阴性的氨苄西林流感嗜血杆菌。